Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Palisade Bio

Cohen's Point72 Pours $14M in This Biotech Stock That Gained 250% in a Month, and Recently Raised $138M in Funding

Steve Cohen's Point72 Asset Management added Palisade Bio to the hedge fund's portfolio amid the company's announcement of positive phase 1 trial data and funding to advance phase 2 trials.

International Business Times UK

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

Steven Cohen's Point72 Asset Management just pulled off what most fund managers only dream of — doubling the SP 500's three-year return — and he's still not easing up. The billionaire investor's next move? A fresh swing into biotech, backing Palisade Bio Inc (NASDAQ:PALI) — a tiny, high-volatility stock working…

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

12 Health Care Stocks Moving In Friday's Intraday Session

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

12 Health Care Stocks Moving In Tuesday's After-Market Session

inkl

Read news from The Economist, FT, and more,
with one subscription

4 Penny Stocks Insiders Are Buying: Heritage Global, Palisade Bio And More

4 Penny Stocks Insiders Are Buying: Heritage Global, Palisade Bio And More

US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment…

FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study

FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study

Palisade Bio Inc (NASDAQ: PALI) has

Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery

Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery

Palisade Bio Inc (NASDAQ: PALI) announced

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Food and Drug Administration

Occidental Petroleum

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

356,617 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play